Related Experiment Video
Updated: Apr 16, 2026

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock
Published on: August 16, 2021
Systemic or Endoventricular Thrombolysis to Treat HeartWare Left Ventricle Assist Device Thrombosis: A Clinical
Giuseppe M Raffa1, Giuseppe D'Ancona1, Sergio Sciacca1
1Cardiac Surgery and Heart Transplantation Unit, Department for the Treatment and Study of Cardiothoracic Diseases and Cardiothoracic Transplantation, Mediterranean Institute for Transplantation and Advanced Specialized Therapies (ISMETT), Palermo, Italy.
Insights
Endoventricular thrombolytic procedures (ETP) for continuous-flow left ventricle assist device (CF-LVAD) thrombosis frequently cause vascular access complications. These complications increase patient risk and healthcare costs, suggesting a need for less invasive treatments.
Area of Science:
- Cardiovascular Surgery
- Medical Devices
- Interventional Cardiology
Background:
- Continuous-flow left ventricle assist devices (CF-LVADs) are crucial for advanced heart failure treatment.
- Pump thrombosis is a significant complication associated with CF-LVADs.
- Endoventricular thrombolytic procedure (ETP) is a treatment option for CF-LVAD thrombosis.
Purpose of the Study:
- To investigate the incidence and types of complications following Endoventricular thrombolytic procedures (ETP) in patients with CF-LVAD thrombosis.
- To assess the safety and risks associated with ETP in this patient population.
Main Methods:
- Retrospective analysis of patients who underwent CF-LVAD implantation and subsequent ETP.
- Review of procedural data, including access routes and complications.
- Analysis of complication rates, such as radial artery occlusion and hematomas.
Main Results:
- Four out of 20 (20%) CF-LVAD patients developed pump thrombosis requiring ETP.
- Nine ETPs were performed, with a high complication rate of 55.5% for vascular access.
- Specific complications included radial artery occlusion (5 ETPs), groin hematomas (2 ETPs), and femoral artery false aneurysm (1 ETP).
Conclusions:
- Endoventricular thrombolytic procedures (ETP) carry a substantial risk of vascular access complications in CF-LVAD patients.
- These complications can exacerbate the existing clinical complexity and economic burden.
- Less invasive treatment strategies for CF-LVAD thrombosis should be considered.
Abstract:
Endoventricular thrombolytic procedure (ETP) has been used to treat continuous-flow left ventricle assist device (CF-LVAD) thrombosis. The study aims to investigate the occurrence of complications after ETP. Data were retrospectively reviewed and analyzed in a series of patients who underwent CF-LVAD followed by ETP. Since November 2010, 20 patients underwent HeartWare CF-LVAD implantation at our institute. Four patients (20%) developed pump thrombosis and underwent a total of nine ETPs with tissue plasminogen activator infused into the left ventricle. The mean age was 60.2 ± 9 years. ETP was performed via either the femoral (n = 6) or radial artery (n = 3). Five ETPs (55.5%) were complicated by left and right radial artery occlusion, two by groin hematomas, and one by femoral artery false aneurysm. ETP carries a strong risk of vascular access complications that, in CF-LVAD patients, may add to the already complex clinical profile and economic burden; thus, a less invasive treatment is advisable whenever required.
Related Concept Videos
Venous Thrombosis III: Interprofessional Care
Cardiomyopathy V: Interprofessional Care
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
Heart Failure VI: Adjunct Therapies
Peripheral Artery Disease III: Interprofessional Care
Cardiac Catheterization III: Left Heart Catheterization

